Release date: 21 September 2021
Promoter – Financial Intermediary
The aim of the project is to improve the company's new COVID-19 PCR-based rapid test and to develop rapid tests against other infectious diseases, such as the ones caused by respiratory or antibiotic-resistant pathogens.
EIB financing will support and accelerate the research, development and innovation (RDI) efforts conducted by the Promoter to improve a new PCR-based diagnostic device and kit for rapid COVID-19 testing, as well as to develop fast, simple and reliable tests for other infectious diseases, targeting multiple pathogens, including the ones responsible for antimicrobial resistance.
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 15 million
Total cost (Approximate amount)
EUR 30 million
The project concerns investments in research and development activities carried out by the Promoter in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal by the EIB regarding the compliance of the project with the relevant European legislation.
The Promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is after all subject to the EU public procurement legislation (Directive 2014/24/EU, where applicable), then the Bank would require the Promoter to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2014/24/EU, where applicable, as well as Directive 89/665/EEC), as interpreted by the Court of Justice of the EU, with publication of tender notices in the Official Journal of the EU, as and where required.
Under appraisal - 21/09/2021
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).